Company

Glenmark Pharmaceuticals

As of the edition of 20 October 2026, Glenmark Pharmaceuticals runs 2 drugs; it is on route A at 4 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Family history

Glenmark Pharmaceuticals was dissolved.

  • Glenmark Pharmaceuticals Europe Ltd. (R&D): dissolved

Drugs by status

StatusCount
Went quiet2
Total2

Where it needs a new molecule

Route A at 4 targets, route B at 0 targets.

Three of its 4 rows, by target and route
TargetRoute
PDE4B 3',5'-cyclic-AMP phosphodiesterase 4BRoute A
PDE4A 3',5'-cyclic-AMP phosphodiesterase 4ARoute A
PDE4C 3',5'-cyclic-AMP phosphodiesterase 4CRoute A

All 4 rows on route A or B

In the product

4 company-target rows on route A or B; 1 is not shown here, and no score is.

Where its trials are

  • Hormones: 1 trials led
  • Immune system: 1 trials led
  • Lungs and airways: 1 trials led